Skip to main content
. Author manuscript; available in PMC: 2008 Aug 1.
Published in final edited form as: Semin Cancer Biol. 2007 Jun 23;17(4):317–329. doi: 10.1016/j.semcancer.2007.06.006

Table III.

Clinical trials of therapeutic cancer vaccines using modified HLA-A*0201-restricted tumor antigens

Cancer Antigen Adjuvant Positive in vitro responses Clinical response Ref
Extensive metastatic melanoma gp100209-217
gp100209-217(210M)
gp100209-217(210M)		 IFA
IFA
IFA+IL-2		 2/8 IFNγ*
10/11 IFNγ*
3/19 IFNγ* 		1/9 CR
0/11 CR,
3/11 MR
8/19 CR,
3/19 MR,
3/19 SD		 [97]
Stage I-III melanoma gp100209-217(210M) IFA +/-
IFNα** 		28/29 tetramer
9/9 IFNγ* 		Not Reported [160]
Melanoma gp100209-217(210M) IFA
IFA+IL-12
IFA+IL-2		 7/7 tetramer*
4/5 tetramer*
2/11 tetramer* 		Not Reported [161]
Stage III/IV melanoma gp100209-217(210M)
tyrosinase368-376 (370D)		 IFA+/-
IL-12		 34/40 Skin test*‡ 33/38 IFNγ*
37/42 tetramer* 		24/48 relapsed, 10 died [162]
Stage IV melanoma gp100209-217(210M)
tyrosinase368-376 (370D)		 DCs 2/16 Skin test* 11/16 IFNγ*
0/16 tetramer* 		1/16 CR
2/16 MR,
2/16 SD
10/16 died		 [163]
Stage IIA/IIB melanoma gp100209-217(210M)
tyrosinase368-376(370D)		 IFA+/-
GM-CSF		 34/39 ELISA
37/42 tetramer		 After 24 months: “favorable:” 7 relapsed, 2 died [164]
Recurrent small cell lung or colon cancer CEA605-613(610D) Flt3 7/12 CTL
10/12 tetramer* 		2 CR, 7 PD
2 SD, 1 MR		 [165]

CR=Complete response, PD=progressive disease, SD=Stable disease, MR=Mixed response, IFA=Incomplete Freund’s adjuvant, DCs=dendritic cells

*

specific for native peptide

‡

response measured to gp100, not tyrosinase

**

IFNα does not interfere with the antigen-specific response.